Disease models - Xylyx Bio

Pathological ECM changes drive disease progression by regulating cell–matrix interactions. Human diseased ECM substrates, including fibrotic liver and lung ECMs, enable clinically-relevant, high-fidelity disease modeling predictive of human disease biology.

Liver ECM

MTHNLV201	Human Normal NativeCoat™ Liver ECM Coating
MTHDLV201	Human Diseased NativeCoat™ Liver ECM Coating
MTHNLV300	Human Normal TissueSpec® ECM Scaffold (custom)
MTHDLV300	Human Diseased TissueSpec® ECM Scaffold (custom)

Lung ECM

MTHNLG201	Human Normal NativeCoat™ Lung ECM Coating
MTHDLG201	Human Diseased NativeCoat™ ECM Coating
MTHNLG300	Human Normal TissueSpec® ECM Scaffold (custom)
MTHDLG300	Human Diseased TissueSpec® ECM Scaffold (custom)

Related Resources

Application Note: Accelerating Antifibrotic Drug Development with Human Fibrotic Liver ECM Substrates

Application Note: Accelerating Antifibrotic Drug Development with Human Fibrotic Lung ECM Substrates

Publication: Fibrotic Human Lung Extracellular Matrix as a Disease-Specific Substrate for Models of Pulmonary Fibrosis (2019)

Poster: Fibrotic Liver Extracellular Matrix Substrates for 3D in-vitro Models of Human Liver Fibrosis

Poster: Fibrotic Lung Extracellular Matrix Substrates for 3D in-vitro Models of Human Pulmonary Fibrosis

Webinar: Transforming Lung Fibrosis Drug Discovery with The IN MATRICO® Human Lung Fibrosis Platform